Clopidogrel following 1-month aspirin-free low-dose prasugrel monotherapy versus aspirin following 1-month DAPT after PCI for patients with ACS or HBR: Final 1-year results from the STOPDAPT-3

31 August 2024 (16:15 - 16:27)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Doctor Hirotoshi Watanabe

Hirakata Kohsai Hospital, Hirakata (Japan)

4 More presentations in this session

Presentation thumbnail

Long-Term Outcomes with PCI Guided by Fractional Flow Reserve

Doctor C. Collet (New York, US)

Presentation thumbnail

Titanium-nitride-oxide-coated vs drug-eluting stents in acute coronary syndromes during five-year follow-up: an individual patient data meta-analysis

Doctor T. Mahendiran (Aalst, BE)

Presentation thumbnail

Physiology-guided complete versus culprit-only PCI in older MI patients

Associate Professor S. Biscaglia (Ferrara, IT)

Presentation thumbnail

A comparison of prolonged anticoagulation versus no anticoagulation after primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction

Associate Professor Y. Yan (Beijing, CN)

Access the full session

Session thumbnail

Trial updates and other studies on percutaneous coronary intervention

The Event

Event poster

ESC Congress 2024

31 August 2024 16:15 CET

You may be interested in

Congress Presentation

STOPDAPT-3: An Aspirin-Free antithrombotic strategy for percutaneous coronary intervention

Congress Presentation

Discussant review - STOPDAPT-3

Congress Presentation

Ticagrelor monotherapy or DAPT after drug-eluting coronary stenting in patients with or without acute coronary syndrome: a patient-level meta-analysis of randomized controlled trials

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources